Encouraging Patients for Biologic Use in Early Treatment of CD

Opinion
Video

Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.

This is a video synopsis/summary of a panel discussion involving Marla Dubinsky, MD; David Rubin, MD; Miguel Regueiro, MD; Remo Panaccione, MD, FRCPC; and Sara Horst, MD, MPH.

In this discussion, the participants emphasize the importance of optimism in managing diseases, particularly focusing on the impact of mood and behavior on outcomes for patients. The conversation explores various therapeutic options available for treating a certain medical condition.

The speakers discuss the evolution of treatment strategies, highlighting the shift from having limited options, such as tumor necrosis factor (TNF) therapy, to a multitude of therapies. The fear of exhausting all treatment options and resorting to a last-resort therapy is addressed, with an emphasis on the positive change in this mindset. Patients are encouraged to embrace the concept that there are several paths of treatment available, and the choice of therapy is not a 1-size-fits-all approach.

The conversation touches upon the idea of a journey in patient care, with the analogy of choosing a path together. The importance of providing hope to patients, especially those on their first biologic therapy, is stressed. The speakers emphasize that if a particular treatment does not work, there are alternative paths to explore, maintaining a sense of optimism.

Addressing patients' concerns about the duration of therapy, the speakers reassure them that it's not necessarily a lifelong commitment. The focus is on using the best available therapy until something better or a cure is found. The rapid advancements in treatment options over the years are highlighted, with a frequent paradigm shift in managing the medical condition.

Overall, the discussion encourages a more proactive and optimistic approach to disease management, assuring patients that there are evolving treatment options and that therapy decisions are not irreversible or confined to a last-resort scenario.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
4 KOLs are featured in this series
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
4 KOLs are featured in this series
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
A panel of 4 experts on asthma
Shauna Applin, ARNP, an expert on HIV
4 KOLs are featured in this series
4 KOLs are featured in this series
© 2024 MJH Life Sciences

All rights reserved.